SEATTLE -- The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, congratulated Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo.

Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI’s proprietary SLA-SE adjuvant. The acquisition underscores the growing recognition of next-generation adjuvants that can deliver improved tolerability and strong immune responses.

“SLA-SE represents a significant advancement in adjuvant technology, designed to elicit robust T-cell immunity with a favorable safety profile,” said Keeley Foley, CEO of AAHI. “We are thrilled that this technology, developed at AAHI, is now positioned to reach people through Lilly’s world-class development and commercial capabilities.”

Importantly, AAHI retains rights to license and develop SLA-SE adjuvant for uses outside the shingles (varicella zoster virus) vaccine field. This includes in combination with other antigens for a wide range of infectious diseases, cancer vaccines, and additional indications.